Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
Bimzelx | bimekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | ||
Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Intrarosa | prasterone | Postmenopausal vulvovaginal atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
Retevmo | selpercatinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Qinlock | ripretinib | Gastrointestinal stromal tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete | ||
Libtayo | cemiplimab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete |